Lung Cancer Metastatic Clinical Trial
Official title:
Routine Neck Ultrasound by Respiratory Physicians in the Diagnosis and Staging of Patients With Lung Cancer and Mediastinal Lymphadenopathy, a Prospective Pilot Study
This is a study of routine neck ultrasound performed by respiratory physicians in patients with mediastinal lymphadenopathy and suspected lung cancer
In the first phase of the study a respiratory physician was trained to perform neck
ultrasound and needle sampling of enlarged cervical lymph nodes according to preset criteria.
In the second phase patients with suspected lung cancer and enlarged mediastinal lymph nodes
underwent routine neck ultrasound and enlarged cervical lymph nodes were sampled using fine
needle and or core needle biopsy.
The outcomes of interest in the study were the rate of malignant cervical lymphadenopathy
defined as pathological evidence of cancer in neck lymph node samples consistent with a lung
primary, adequacy of needle sampling, patient reported experience assessed by a visual
analogue of discomfort associated with needle neck sampling and EBUS, and the proportion of
patients that had nodal upstaging
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05452005 -
Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT03179150 -
Clinical Validation of the M5L Lung CAD
|
N/A | |
Recruiting |
NCT03693339 -
Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation
|
Phase 2 | |
Completed |
NCT03184571 -
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC
|
Phase 2 | |
Terminated |
NCT02308865 -
Early Palliative Care in Metastatic Lung Cancer in Northern France
|
N/A | |
Not yet recruiting |
NCT03703596 -
Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC
|
Phase 2 | |
Terminated |
NCT04069936 -
Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC
|
Phase 2 | |
Recruiting |
NCT05537922 -
I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
|
||
Active, not recruiting |
NCT04986670 -
NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer
|
N/A | |
Completed |
NCT03755102 -
A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.
|
Early Phase 1 | |
Not yet recruiting |
NCT03638765 -
Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer
|
Phase 1 | |
Recruiting |
NCT02976740 -
SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy
|
Phase 2 | |
Recruiting |
NCT04085315 -
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03693326 -
PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalities
|
Phase 2 | |
Recruiting |
NCT05860296 -
Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04964960 -
Pembro+Chemo in Brain Mets
|
Phase 2 | |
Completed |
NCT04973436 -
DBT for Metastatic Lung Cancer
|
N/A | |
Recruiting |
NCT05078047 -
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients With Metastatic Cancer in Response After 6 Months of Standard IO
|
Phase 3 | |
Active, not recruiting |
NCT03057106 -
Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC
|
Phase 2 | |
Recruiting |
NCT05144529 -
A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC
|
Phase 2 |